Impel NeuroPharma

Impel NeuroPharma is a Seattle-based company developing intranasal drug treatments for central nervous system (CNS) disorders. Impel has developed a novel drug delivery platform, the POD technology, that administers drug to the deep nasal cavity to improve the brain distribution of many drugs. Impel’s proprietary (POD) device technology enables entirely new categories of drugs, including biologics, to be delivered to the central nervous system using a cost-effective, disposable, non-invasive intranasal drug delivery device.

The goal at Impel is simple: we want to develop the next generation of therapeutics for central nervous system (CNS) disorders. Patients with CNS disorders are vastly underserved by current therapeutics and we are working hard to change that. Impel has built the POD drug delivery platform to allow entire classes of molecules to reach the brain that never could before. Impel has expanded its scope to both partnership with pharmaceutical companies and the development of our own drug products compatible with the POD platform. We take a comprehensive approach to development and design considering patient comfort, regulatory approval pathways, and cost effectiveness. Treatments currently under development include therapies for migraine, Alzheimer’s disease, Parkinson’s disease, and pain relief

Type
Private
HQ
Seattle, US
Founded
2008
Employees
23 (est)-4%
Impel NeuroPharma was founded in 2008 and is headquartered in Seattle, US

Impel NeuroPharma Locations

Seattle, US

Impel NeuroPharma Metrics

Impel NeuroPharma Summary

Founding Date

2008

Total Funding

$40.6 M

Latest funding size

$36 M

Time since last funding

about 2 months

Investors

We estimate that Impel NeuroPharma's latest funding round in December 2016 was $36 M. In total, Impel NeuroPharma has raised $40.6 M

Impel NeuroPharma Online Presence

Impel NeuroPharma Company Life

You may also be interested in